Medical Equipment/Supplies/Accessories · Founded 1995 · www.centenialindia.com · BSE 531380 · · ISIN INE405H01018
No Notes Added Yet
Here's a structured overview of Centenial Surgical Suture Ltd. based on the provided information:
Centenial Surgical Suture Ltd.
1. Business Overview
Centenial Surgical Suture Ltd. is an Indian company operating in the Medical Equipment/Supplies/Accessories sector. Based on its name, the company's core business involves the manufacturing and/or distribution of surgical sutures. It likely operates on a Business-to-Business (B2B) model, supplying its products to hospitals, surgical centers, clinics, and potentially other medical institutions and distributors across India. The company generates revenue through the direct sale of these essential medical consumables required for surgical procedures and wound closure.
2. Key Segments / Revenue Mix
Given the company's name, its primary and dominant business segment is the production and sale of surgical sutures. While it may potentially offer related wound care products or other surgical disposables, surgical sutures are expected to constitute the vast majority of its revenue. Specific segment contribution percentages are not available from the provided information.
3. Industry & Positioning
The company operates within the broader Indian medical equipment and supplies industry, specifically targeting the surgical disposables market. This industry is characterized by a mix of large multinational corporations and numerous domestic manufacturers. The market for surgical sutures is generally competitive, with players competing on product quality, material types (e.g., absorbable vs. non-absorbable, monofilament vs. braided), price, regulatory approvals, and distribution reach. Centenial Surgical Suture Ltd. likely positions itself by leveraging domestic manufacturing, potentially offering competitive pricing, and building a distribution network within India to serve a range of healthcare providers.
4. Competitive Advantage (Moat)
Without specific company details, potential competitive advantages for Centenial Surgical Suture Ltd. could include:
Distribution Network: A well-established and efficient sales and distribution network across India, allowing broad access to hospitals and surgeons.
Cost Efficiency: As a domestic manufacturer, it might benefit from lower production costs compared to imports, enabling competitive pricing.
Brand Reputation: A long-standing reputation for quality and reliability among surgeons and procurement departments can foster loyalty, given the critical nature of surgical products.
Regulatory Expertise: Proficiency in navigating India's medical device regulations for quick product approvals and market access.
High switching costs are less typical for standard sutures, though surgeons' familiarity with specific brands can create some inertia.
5. Growth Drivers
Healthcare Infrastructure Expansion: The ongoing growth and modernization of hospitals and surgical facilities in India.
Increasing Surgical Procedures: Rising prevalence of chronic diseases, increasing access to healthcare, and a growing population leading to a higher volume of surgical interventions.
Growing Healthcare Expenditure: Continued increase in public and private spending on healthcare across India.
"Make in India" Initiative: Government policies promoting domestic manufacturing could provide a favorable operating environment and reduce import dependency.
Export Opportunities: Potential to expand sales to international markets, particularly in developing economies.
6. Risks
Intense Competition: Fierce competition from both domestic players and larger multinational companies, leading to pricing pressure and margin erosion.
Regulatory Changes: Evolving medical device regulations in India could impose higher compliance costs or restrict market access for certain products.
Supply Chain Volatility: Dependence on raw material availability and pricing, which can be subject to global supply chain disruptions.
Product Liability: Risk of legal claims related to product quality or performance in a critical application like surgery.
Technological Obsolescence: Potential for new wound closure technologies or materials to emerge, requiring continuous R&D investment.
Price Sensitivity: Hospitals and government procurement bodies often prioritize cost-effectiveness, impacting profit margins.
7. Management & Ownership
As is common for many Indian companies, Centenial Surgical Suture Ltd. is likely promoter-driven, with the founding family or group holding a significant stake and strategic control. Management quality would be critical in navigating the complex regulatory landscape, managing production, and expanding market reach. Given its listed status, there would be public shareholders alongside the promoters.
8. Outlook
Centenial Surgical Suture Ltd. operates in a fundamentally growing market driven by India's expanding healthcare needs. The bull case suggests the company is well-positioned to capitalize on increasing surgical volumes, potential for 'Make in India' tailwinds, and expanding its distribution network. Its focus on a critical consumable product offers a stable demand base. The bear case highlights significant competitive pressures from established domestic and international players, potential for pricing wars, and the need for continuous product innovation and quality control in a highly regulated environment. Regulatory shifts or disruptions in the supply chain for raw materials could also pose challenges. Its success will depend on its ability to maintain product quality, manage costs effectively, and strengthen its market presence in a competitive landscape.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 12 | 12 | 14 | 14 | 12 | 13 | 13 | 13 | 15 | 13 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 12 | 12 | 14 | 14 | 12 | 13 | 13 | 14 | 15 | 13 |
| Total Expenditure | 11 | 11 | 12 | 13 | 11 | 11 | 12 | 12 | 13 | 12 |
| Operating Profit | 1 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 1 |
| Interest | 1 | 1 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | -1 | -1 | -0 | -0 | 0 | -2 |
| Provision for Tax | 0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 0 | 0 | 0 | 0 | -1 | -1 | -0 | -0 | 0 | -2 |
| Adjustments | 0 | 0 | -0 | 0 | 0 | -0 | 0 | -0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | 0 | 0 | -1 | -1 | -0 | -0 | 0 | -2 |
| Adjusted Earnings Per Share | 0.8 | 0.5 | 0.8 | 0.3 | -2.3 | -3.2 | -0.1 | -0 | 0.4 | -6.3 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 52 | 51 | 53 | 53 | 56 | 56 | 37 | 44 | 53 | 51 | 54 | 54 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 52 | 51 | 53 | 53 | 56 | 56 | 37 | 44 | 53 | 51 | 54 | 55 |
| Total Expenditure | 47 | 47 | 48 | 48 | 51 | 50 | 32 | 40 | 48 | 46 | 47 | 49 |
| Operating Profit | 5 | 5 | 5 | 5 | 5 | 6 | 5 | 5 | 5 | 5 | 7 | 5 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 4 | 4 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 3 | 2 | 3 | 2 | 3 | 2 | 2 | 1 | 1 | 1 | -2 | -2 |
| Provision for Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | -0 | 0 |
| Profit After Tax | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | -1 | -2 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | -1 | -2 |
| Adjusted Earnings Per Share | 5.2 | 4.3 | 4.7 | 4.2 | 5.5 | 3.6 | 2.6 | 1.7 | 2.4 | 3.1 | -4 | -6 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 6% | 7% | -1% | 0% |
| Operating Profit CAGR | 40% | 12% | 3% | 3% |
| PAT CAGR | -200% | NAN% | NAN% | NAN% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -40% | 7% | 9% | 4% |
| ROE Average | -5% | 1% | 2% | 5% |
| ROCE Average | 5% | 7% | 8% | 11% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 21 | 23 | 24 | 26 | 28 | 29 | 30 | 30 | 31 | 32 | 31 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2 | 2 | 2 | 2 | 1 | 9 | 8 | 7 | 6 | 14 | 22 |
| Total Current Liabilities | 31 | 27 | 28 | 26 | 26 | 31 | 32 | 24 | 29 | 33 | 32 |
| Total Liabilities | 55 | 53 | 56 | 55 | 57 | 69 | 70 | 61 | 66 | 79 | 85 |
| Fixed Assets | 4 | 4 | 4 | 4 | 4 | 10 | 9 | 8 | 6 | 13 | 20 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 2 |
| Total Current Assets | 51 | 49 | 52 | 51 | 52 | 58 | 61 | 53 | 59 | 65 | 63 |
| Total Assets | 55 | 53 | 56 | 55 | 57 | 69 | 70 | 61 | 66 | 79 | 85 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
| Cash Flow from Operating Activities | 0 | -2 | -0 | 2 | 2 | 2 | 2 | 5 | 1 | 6 | 17 |
| Cash Flow from Investing Activities | -0 | -0 | -2 | -1 | -1 | -1 | -1 | -0 | -0 | -8 | -12 |
| Cash Flow from Financing Activities | 1 | 1 | 2 | -1 | -1 | -0 | -1 | -5 | -1 | 2 | -6 |
| Net Cash Inflow / Outflow | 1 | -1 | -0 | 0 | -1 | 0 | -0 | -0 | 0 | 0 | -0 |
| Closing Cash & Cash Equivalent | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 5.25 | 4.28 | 4.71 | 4.23 | 5.53 | 3.55 | 2.64 | 1.72 | 2.43 | 3.11 | -4.01 |
| CEPS(Rs) | 7.53 | 6.13 | 6.32 | 5.87 | 7.43 | 7.81 | 6.89 | 5.9 | 5.99 | 6.91 | 7.65 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 53.29 | 57.57 | 62.28 | 66.51 | 72.03 | 73.55 | 76.19 | 77.91 | 80.33 | 83.44 | 79.43 |
| Core EBITDA Margin(%) | 9.05 | 8.69 | 9.08 | 8.46 | 9.44 | 10.65 | 13.83 | 10.09 | 8.36 | 10.06 | 11.99 |
| EBIT Margin(%) | 8.28 | 7.48 | 8.17 | 7.44 | 8.44 | 8.02 | 9.88 | 6.76 | 6.13 | 7.6 | 4.27 |
| Pre Tax Margin(%) | 5.27 | 4.35 | 4.82 | 4.58 | 5.07 | 3.87 | 4.14 | 2.42 | 2.78 | 2.49 | -3.02 |
| PAT Margin (%) | 3.48 | 2.87 | 3.25 | 2.92 | 3.6 | 2.33 | 2.6 | 1.41 | 1.68 | 2.22 | -2.73 |
| Cash Profit Margin (%) | 4.99 | 4.11 | 4.36 | 4.06 | 4.84 | 5.12 | 6.8 | 4.85 | 4.15 | 4.93 | 5.22 |
| ROA(%) | 3.64 | 2.89 | 3.17 | 2.77 | 3.6 | 2.06 | 1.38 | 0.95 | 1.39 | 1.56 | -1.79 |
| ROE(%) | 10.37 | 7.72 | 7.86 | 6.56 | 7.98 | 4.88 | 3.52 | 2.23 | 3.07 | 3.8 | -4.93 |
| ROCE(%) | 14.22 | 11.74 | 14.02 | 14.84 | 16.75 | 12.64 | 8.65 | 7.27 | 8.02 | 8.87 | 5.09 |
| Receivable days | 127.54 | 128.23 | 129.93 | 128.11 | 126.33 | 144.58 | 226.09 | 172.23 | 139.05 | 140.46 | 126.86 |
| Inventory Days | 135.98 | 153.42 | 183.5 | 208.31 | 196.63 | 203.52 | 338.14 | 281.38 | 240.91 | 284.36 | 293.26 |
| Payable days | 249.01 | 221.97 | 136.29 | 138.3 | 125.05 | 156.01 | 406.55 | 177.73 | 189.11 | 234.8 | 178.88 |
| PER(x) | 9.91 | 15.85 | 15.64 | 19.4 | 8.94 | 9.8 | 16.22 | 35.34 | 25.4 | 29.38 | 0 |
| Price/Book(x) | 0.98 | 1.18 | 1.18 | 1.23 | 0.69 | 0.47 | 0.56 | 0.78 | 0.77 | 1.09 | 1.38 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.57 | 0.71 | 0.52 | 0.57 | 0.34 | 0.44 | 0.77 | 0.7 | 0.61 | 0.92 | 0.97 |
| EV/Core EBITDA(x) | 5.44 | 7.74 | 5.56 | 6.64 | 3.48 | 4.11 | 5.49 | 6.89 | 7.08 | 8.92 | 7.98 |
| Net Sales Growth(%) | 1.49 | -0.6 | 2.7 | -0.18 | 6.27 | -0.79 | -33.59 | 20.29 | 18.52 | -2.78 | 4.55 |
| EBIT Growth(%) | 12.34 | -10.6 | 6.01 | -9.05 | 20.47 | -5.68 | -18.21 | -17.74 | 7.59 | 20.42 | -41.27 |
| PAT Growth(%) | 6.91 | -18.5 | 10.13 | -10.28 | 30.76 | -35.74 | -25.78 | -34.8 | 41.27 | 28.04 | -229.03 |
| EPS Growth(%) | 6.91 | -18.5 | 10.13 | -10.28 | 30.76 | -35.74 | -25.78 | -34.8 | 41.27 | 28.04 | -229.03 |
| Debt/Equity(x) | 0.58 | 0.58 | 0.05 | 0.05 | 0.04 | 0.44 | 0.46 | 0.31 | 0.32 | 0.45 | 0.4 |
| Current Ratio(x) | 1.65 | 1.83 | 1.83 | 1.94 | 2 | 1.87 | 1.92 | 2.2 | 2.04 | 1.99 | 1.98 |
| Quick Ratio(x) | 0.93 | 0.94 | 0.78 | 0.78 | 0.86 | 0.83 | 0.77 | 0.87 | 0.76 | 0.69 | 0.61 |
| Interest Cover(x) | 2.75 | 2.39 | 2.44 | 2.59 | 2.5 | 1.93 | 1.72 | 1.56 | 1.83 | 1.49 | 0.59 |
| Total Debt/Mcap(x) | 0.65 | 0.53 | 0.04 | 0.04 | 0.07 | 1 | 0.86 | 0.42 | 0.44 | 0.43 | 0.31 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 46.89 | 46.89 | 46.89 | 46.89 | 46.89 | 46.89 | 46.89 | 46.89 | 46.89 | 46.89 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 53.11 | 53.11 | 53.11 | 53.11 | 53.11 | 53.11 | 53.11 | 53.11 | 53.11 | 53.11 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +6% | +7% | -1% | 0% |
| Operating Profit CAGR | +40% | +12% | +3% | +3% |
| PAT CAGR | -200% | 0% | 0% | 0% |
| Share Price CAGR | -40% | +7% | +9% | +4% |
| ROE Average | -5% | +1% | +2% | +5% |
| ROCE Average | +5% | +7% | +8% | +11% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 46.89 | 46.89 | 46.89 | 46.89 | 46.89 | 46.89 | 46.89 | 46.89 | 46.89 | 46.89 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 53.11 | 53.11 | 53.11 | 53.11 | 53.11 | 53.11 | 53.11 | 53.11 | 53.11 | 53.11 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.